Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | GDC-6036 |
Trade Name | |
Synonyms | GDC6036|GDC 6036 |
Drug Descriptions |
GDC-6036 is a selective inhibitor of KRAS G12C that blocks downstream signaling, and may lead to anti-tumor activity (Annals of Oncology (2022) 33 (suppl_7): S197-S224). |
DrugClasses | KRAS G12C inhibitor 28 |
CAS Registry Number | NA |
NCIT ID | C173995 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + GDC-6036 | Atezolizumab GDC-6036 | 0 | 1 |
Bevacizumab + GDC-6036 | Bevacizumab GDC-6036 | 0 | 1 |
Cetuximab + GDC-6036 | Cetuximab GDC-6036 | 0 | 1 |
Erlotinib + GDC-6036 | Erlotinib GDC-6036 | 0 | 1 |
GDC-6036 | GDC-6036 | 0 | 1 |
GDC-6036 + RLY-1971 | GDC-6036 RLY-1971 | 0 | 0 |